Assyro AI

FDA Orange Book · active-ingredient family

Nelfinavir mesylate

Nelfinavir mesylate is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:VIRACEPT · NDA 021503

3

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · powder, tablet

ProductApplicantApplicationTEApproved
VIRACEPTRLDAGOURON PHARMSNDA 021503Apr 30, 2003
VIRACEPTRLDAGOURON PHARMSNDA 020779Mar 14, 1997
VIRACEPTAGOURON PHARMSNDA 020778Mar 14, 1997

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Nelfinavir mesylate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.